Trials
Search / Trial NCT05636228

Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis

Launched by INVIRSA, INC. · Nov 23, 2022

Trial Information

Current as of February 05, 2025

Completed

Keywords

Pink Eye Conjunctivitis

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Male or female patient ≥ 18 years of age
  • A clinical diagnosis of AIK with a minimum of a 2+ (moderate) conjunctival hyperemia and a minimum of 1+ (mild) discharge (whether it be watery or purulent) in at least one eye
  • Exclusion Criteria:
  • Untreated keratoconjunctivitis of any type that has lasted 96 consecutive hours or more prior to baseline visit
  • Infectious blepharitis as the primary cause of ocular hyperemia and discharge in the opinion of the investigator (Note: If the blepharitis is secondary to the conjunctivitis, the patient can be included)
  • Suspected allergic conjunctivitis as a primary cause of conjunctival hyperemia (bulbar redness) and/or discharge in the opinion of the Investigator
  • Suspected corneal ulcer
  • Ocular topical steroid use within two weeks prior to baseline visit
  • Ocular topical antibiotic use for less than 24 hours or greater than 96 hours of dosing prior to Baseline visit (this does NOT exclude naïve patients or patients that have not taken topical antibiotics)
  • Ocular topical povidone iodine use within 1 week prior to baseline visit
  • Systemic antibiotic use within 2 weeks prior to baseline visit
  • Ocular topical or systemic anti-fungal within 2 weeks prior to baseline visit
  • Ocular topical or systemic anti-viral use within 2 weeks prior to baseline visit
  • Corticosteroid (including but not limited to oral, intranasal, inhaled, topical, etc.) or any immunosuppressant use within 30 days prior to Baseline visit
  • On current treatment for herpes keratitis (evidence of herpes keratitis and/or ocular dendrites can be included)
  • Known or suspected ocular fungal infection or ocular microsporidia infection

About Invirsa, Inc.

Invirsa, Inc. is a biopharmaceutical company dedicated to advancing innovative therapies for the prevention and treatment of viral infections and related diseases. With a focus on harnessing cutting-edge technologies, Invirsa is committed to developing novel antiviral solutions that address unmet medical needs. The company’s research initiatives are guided by a robust scientific foundation and a strong emphasis on clinical efficacy and safety. Through strategic partnerships and collaborations, Invirsa aims to bring transformative therapies to market, improving patient outcomes and enhancing public health globally.

Locations

Bangkok, , Thailand

Bangkok, , Thailand

Bangkok, , Thailand

Glendale, California, United States

Miami, Florida, United States

Pasadena, California, United States

Largo, Florida, United States

Athens, Ohio, United States

Miami Beach, Florida, United States

Miami, Florida, United States

Bangkok, , Thailand

Bangkok, , Thailand

Pittsburg, Kansas, United States

Garner, North Carolina, United States

Lakeway, Texas, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials